Advertisement

What Chemotherapy Is Practicable in Aged Patients?

  • Carmelo Pozzo
  • Ernesto Rossi
Chapter

Abstract

The number of elderly patients diagnosed with rectal cancer (RC) is very high and, considering colon and rectal cancer (CRC), is one of the leading causes of cancer-related death in the elderly [1]. However, the number of older patients enrolled in clinical trials is underrepresented and in most cases elderly population undertreated. Although, with the introduction of new treatments and better diagnostic techniques and surgical procedures, a better outcome is achievable today also in elderly patients diagnosed with resectable or metastatic rectal cancer, overall survival rate remains low. This is probably due to less aggressive diagnostic evaluation; less intensive chemotherapy, including anticipatory drug dose reduction or empiric schedule alteration; less aggressive surgery; and, finally yet importantly, also social conditions and limited access to healthcare system of elderly population with cancer.

References

  1. 1.
    Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, Wingo PA, Jemal A, Feigal EG (2002) Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. Cancer burden. Cancer 94(10):2766–2792CrossRefPubMedGoogle Scholar
  2. 2.
    Extermann M, Hurria A (2007) Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 25:1824–1831CrossRefPubMedGoogle Scholar
  3. 3.
    Rodin MB, Mohile SG (2007) A practical approach to geriatric assessment in oncology. J Clin Oncol 25:1936–1944CrossRefPubMedGoogle Scholar
  4. 4.
    Hurria A, Gupta S, Zauderer M, Zuckerman EL, Cohen HJ, Muss H, Rodin M, Panageas KS, Holland JC, Saltz L et al (2005) Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104:1998–2005CrossRefPubMedGoogle Scholar
  5. 5.
    Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29:3457–3465CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M (2007) Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg 246:215–221CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Shahir MA, Lemmens VE, van de Poll-Franse LV, Voogd AC, Martijn H, Janssen-Heijnen ML (2006) Elderly patients with rectal cancer have a higher risk of treatment-related complications and a poorer prognosis than younger patients: a population-based study. Eur J Cancer 42:3015–3021CrossRefPubMedGoogle Scholar
  8. 8.
    Neugut AI, Fleischauer AT, Sundararajan V, Mitra N, Heitjan DF, Jacobson JS, Grann VR (2002) Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J ClinOncol 20:2643–2650CrossRefGoogle Scholar
  9. 9.
    Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 358:1291–1304CrossRefGoogle Scholar
  10. 10.
    Martling A, Holm T, Johansson H, Rutqvist LE, Cedermark B (2001) The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: long-term follow-up of a population-based study. Cancer 92:896–902CrossRefPubMedGoogle Scholar
  11. 11.
    Ooi BS, Tjandra JJ, Green MD (1999) Morbidities of adjuvant chemotherapy and radiotherapy for resectable rectal cancer: an overview. Dis Colon Rectum 42:403–418CrossRefPubMedGoogle Scholar
  12. 12.
    Farniok KE, Levitt SH (1994) The role of radiation therapy in the treatment of colorectal cancer. Implications for the older patient. Cancer 74:2154–2159CrossRefPubMedGoogle Scholar
  13. 13.
    Mantello G, Berardi R, Cardinali M, Fabbietti L, Fenu F, Montisci M, Iovini G, Delprete S, Mattioli R, Cascinu S et al (2005) Feasibility of preoperative chemoradiation in rectal cancer patients aged 70 and older. J Exp Clin Cancer Res 24:541–546PubMedGoogle Scholar
  14. 14.
    Ausili Cèfaro G, Genovesi D, Vinciguerra A, Augurio A, Di Tommaso M, Marchese R, Borzillo V, Tasciotti L, Taraborrelli M, Innocenti P et al (2012) Effects of preoperative radiochemotherapy with capecitabine for resectable locally advanced rectal cancer in elderly patients. Tumori 98:622–629CrossRefPubMedGoogle Scholar
  15. 15.
    Pasetto LM, Friso ML, Pucciarelli S, Basso U, Falci C, Bortolami A, Toppan P, Agostini M, Rugge M, Serpentini S et al (2006) Rectal cancer neoadjuvant treatment in elderly patients. Anticancer Res 26:3913–3923PubMedGoogle Scholar
  16. 16.
    Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, Blaszkowsky LS, Clark J, Willett CG, Hong TS (2011) Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys 81:e735–e741CrossRefPubMedGoogle Scholar
  17. 17.
    Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, Sanguineti O, Repetto L, Rosso R (1998) Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 42:336–340CrossRefPubMedGoogle Scholar
  18. 18.
    Magné N, François E, Broisin L, Guardiola E, Ramaïoli A, Ferrero JM, Namer M (2002) Palliative 5-fluorouracil-based chemotherapy for advanced colorectal cancer in the elderly: results of a 10-year experience. Am J Clin Oncol 25:126–130CrossRefPubMedGoogle Scholar
  19. 19.
    Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H et al (2004) Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15:1330–1338CrossRefPubMedGoogle Scholar
  20. 20.
    Feliu J, Escudero P, Llosa F, Bolaños M, Vicent JM, Yubero A, Sanz-Lacalle JJ, Lopez R, Lopez-Gómez L, Casado E et al (2005) Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. J Clin Oncol 23:3104–3111CrossRefPubMedGoogle Scholar
  21. 21.
    Jackson NA, Barrueco J, Soufi-Mahjoubi R, Marshall J, Mitchell E, Zhang X, Meyerhardt J (2009) Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer 115:2617–2629CrossRefPubMedGoogle Scholar
  22. 22.
    Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21:807–814CrossRefPubMedGoogle Scholar
  23. 23.
    Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N et al (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med 343:905–914CrossRefPubMedGoogle Scholar
  24. 24.
    André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V et al (1999) CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35:1343–1347CrossRefPubMedGoogle Scholar
  25. 25.
    Kim TW, Kang WK, Chang HM, Park JO, Ryoo BY, Ahn JS, Zang DY, Lee KH, Kang YK, Kim SR et al (2005) Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean cancer study group trial. Acta Oncol 44:230–235CrossRefPubMedGoogle Scholar
  26. 26.
    Folprecht G, Seymour MT, Saltz L, Douillard JY, Hecker H, Stephens RJ, Maughan TS, Van Cutsem E, Rougier P, Mitry E et al (2008) Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26:1443–1451CrossRefPubMedGoogle Scholar
  27. 27.
    Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, O’Mahony MS, Maughan TS, Parmar M, Langley RE (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377:1749–1759CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Figer A, Perez-Staub N, Carola E, Tournigand C, Lledo G, Flesch M, Barcelo R, Cervantes A, André T, Colin P et al (2007) FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 110:2666–2671CrossRefPubMedGoogle Scholar
  29. 29.
    Cassidy J, Saltz LB, Giantonio BJ, Kabbinavar FF, Hurwitz HI, Rohr UP (2010) Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies. J Cancer Res Clin Oncol 136:737–743CrossRefPubMedGoogle Scholar
  30. 30.
    Kozloff MF, Berlin J, Flynn PJ, Kabbinavar F, Ashby M, Dong W, Sing AP, Grothey A (2010) Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 78:329–339CrossRefPubMedGoogle Scholar
  31. 31.
    Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin DB, Jonker D, Osborne S, Andre N, Waterkamp D et al (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14:1077–1085CrossRefPubMedGoogle Scholar
  32. 32.
    Bouchahda M, Macarulla T, Spano JP, Bachet JB, Lledo G, Andre T, Landi B, Tabernero J, Karaboué A, Domont J et al (2008) Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. Crit Rev Oncol Hematol 67:255–262CrossRefPubMedGoogle Scholar
  33. 33.
    Fornaro L, Baldi GG, Masi G, Allegrini G, Loupakis F, Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C et al (2011) Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. Crit Rev Oncol Hematol 78:243–251CrossRefPubMedGoogle Scholar
  34. 34.
    Sastre J, Aranda E, Grávalos C, Massutí B, Varella-Garcia M, Rivera F, Soler G, Carrato A, Manzano JL, Díaz-Rubio E et al (2011) First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). Crit Rev Oncol Hematol 77:78–84CrossRefPubMedGoogle Scholar
  35. 35.
    Sastre J, Grávalos C, Rivera F, Massuti B, Valladares-Ayerbes M, Marcuello E, Manzano JL, Benavides M, Hidalgo M, Díaz-Rubio E et al (2012) First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study. Oncologist 17:339–345CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  1. 1.Oncolgia Medica, Fondazione Policlinico A. GemelliUniversità Cattolica del Sacro CuoreRomeItaly

Personalised recommendations